Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.
about
Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancerMEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivoTargeted treatment of differentiated and medullary thyroid cancer.Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registryCharacterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models.Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAFRET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer.Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing programHow to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid CancerMultikinase inhibitors: a new option for the treatment of thyroid cancer.Translational research in endocrine surgery.Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.Sorafenib induces partial response in metastatic medullary thyroid carcinoma.An evaluation and recommendation of the optimal methodologies to detect RET gene rearrangements in papillary thyroid carcinoma.CCDC6: the identity of a protein known to be partner in fusion.Sorafenib in the treatment of thyroid cancer.
P2860
Q33598561-B4128E3D-C4D6-4BA7-9D14-5C3D45E1254AQ34109756-C49DC63C-A1E3-4C09-83AA-868FD1E97DEFQ35147151-D725E521-2788-4E7F-ACC2-4BA5C7FA541BQ35169273-C67339FF-F6AF-48D3-9EB7-45C2DAFF1608Q35554680-91A03808-E6E5-412C-8D71-AD5F3BC3A7ABQ35891218-77E2D250-7DAF-4217-A913-3F143490C682Q35914464-577A8249-135A-4299-AB42-9E61EC54C72AQ36530631-3E6A976A-CDB0-4095-BF73-592717F46185Q37295112-BA6811F0-5465-48F6-A75B-75EBEBF36E84Q37902072-8BB43892-64D8-46A5-8047-E5D3FD02D305Q37921602-1076E72F-6B5C-45B4-BC44-866882E9A6B3Q38135137-82FDF415-F0E7-43A8-9FBF-EDDB318E2FF3Q41923524-5130A140-351A-4F50-AFF5-C8031BB27AF3Q42680715-3E9D44CD-C62D-4EBE-97A4-0185101CD94DQ43285102-05C5CBB4-94E0-4BE1-BA9E-A0FDAB80A367Q44116793-72E98FB9-3A12-409D-889B-D43394D0591BQ47634740-9636A2C5-7466-4A86-8341-F15149C3B4DEQ55053748-E769D5FD-6921-4D5E-BFAB-0D4106E483B1
P2860
Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Sorafenib potently inhibits pa ...... boring RET/PTC1 rearrangement.
@ast
Sorafenib potently inhibits pa ...... boring RET/PTC1 rearrangement.
@en
type
label
Sorafenib potently inhibits pa ...... boring RET/PTC1 rearrangement.
@ast
Sorafenib potently inhibits pa ...... boring RET/PTC1 rearrangement.
@en
prefLabel
Sorafenib potently inhibits pa ...... boring RET/PTC1 rearrangement.
@ast
Sorafenib potently inhibits pa ...... boring RET/PTC1 rearrangement.
@en
P2093
P2860
P1476
Sorafenib potently inhibits pa ...... boring RET/PTC1 rearrangement.
@en
P2093
Gary L Clayman
Soon-Hyun Ahn
Ya'an Kang
Ying C Henderson
P2860
P304
P356
10.1158/1078-0432.CCR-07-1772
P407
P577
2008-08-01T00:00:00Z